Showcases Stock ranks Forex

Bristol-Myers Squibb Company (BMY)
57.6  -0.21 (-0.36%) 10-22 16:00
Open: 57.81 Pre. Close: 57.81
High: 58.09 Low: 57.435
Volume: 6,669,376 Market Cap: 127,994M
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. The company's products include Opdivo for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia for adult patients with active RA and prostate-specific antigen, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, it offers Reyataz, a protease inhibitor to treat human immunodeficiency virus (HIV); Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. The company has collaboration agreements with Pfizer, Otsuka, Ono, Nektar, GRYT Health, Ubiquigent Limited, and Sensyne Health plc; clinical collaboration agreement with NeoImmuneTech, Inc.; partnership with Astrazeneca Plc.; and a discovery collaboration with Insitro, Inc. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 58.115 - 58.506 58.506 - 58.829
Low: 56.682 - 57.067 57.067 - 57.387
Close: 57.037 - 57.661 57.661 - 58.178
Stock Technical Analysis
Target: Six months: 69.59
One year: 71.69
Support: Support1: 56.66
Support2: 47.14
Resistance: Resistance1: 59.58
Resistance2: 61.38
Pivot: 57.94
Moving Averages: MA(5): 57.60
MA(20): 58.41
MA(100): 64.67
MA(250): 63.58
MACD: MACD(12,26): -1.27
Signal(12,26,9): -1.49
%K %D: %K(14,3): 32.69
%D(3): 28.26
RSI: RSI(14): 36.99
52-Week: High: 69.75
Low: 56.66
Change(%): -3.5
Average Vol(K): 3-Month: 941515
10-Days: 963640
Price, MAs and Bollinger Bands
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.

BMY has closed above bottom band by 38.8%. Bollinger Bands are 20.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Fri, 22 Oct 2021
Bristol-Myers Makes Takeover Approach to Aurinia Pharmaceuticals - Bloomberg

Fri, 22 Oct 2021
What is in Store for Bristol-Myers (BMY) in Q3 Earnings? - Nasdaq

Fri, 22 Oct 2021
Investors in Bristol-Myers Squibb (NYSE:BMY) have made a return of 29% over the past three years - Simply Wall St

Wed, 20 Oct 2021
Bristol-Myers Plans to Exit Acceleron Stake With Merck Deal - Bloomberg

Tue, 19 Oct 2021
Bristol-Myers Squibb: Oversold Big Pharma - Seeking Alpha

Mon, 11 Oct 2021
Is Bristol-Myers Squibb Co (BMY) Stock a Smart Value Monday? - InvestorsObserver

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Drug Manufacturers—General
Shares Out. (M) 2230.00
Shares Float (M) 2190.00
% Held by Insiders 0.07
% Held by Institutions 75.45
Shares Short (K) 20320
Shares Short Prior Month (K) 21910
Stock Financials
EPS -2.760
Book Value (p.s.) 16.840
Profit Margin -11.44
Operating Margin 18.55
Return on Assets (ttm) 4.3
Return on Equity (ttm) -11.8
Qtrly Rev. Growth 15.5
Gross Profit (p.s.) 15.269
Sales Per Share 19.901
EBITDA (p.s.) 8.448
Qtrly Earnings Growth
Operating Cash Flow (M) 12510.00
Levered Free Cash Flow (M) 9860.00
Stock Valuation
PE Ratio -20.87
PEG Ratio
Price to Book value 3.42
Price to Sales 2.89
Price to Cash Flow 10.27
Stock Dividends
Dividend 1.880
Dividend Yield 0.03
Dividend Growth 1.960

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator